General Information of Drug (ID: DMX71K9)

Drug Name
1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione Drug Info
Synonyms
Apoptosis Activator 2; 79183-19-0; 1-(3,4-Dichlorobenzyl)-1H-indole-2,3-dione; Apoptosis Activator II; 1-(3,4-dichlorobenzyl)indoline-2,3-dione; MDK83190; 1-[(3,4-dichlorophenyl)methyl]indole-2,3-dione; J-503075; 1H-Indole-2,3-dione,1-[(3,4-dichlorophenyl)methyl]-; SR-01000411093; ApoptosisActivator2; AC1LYJSJ; Tocris-2098; AC1Q3JHQ; CBMicro_042945; Isatin-based compound, 16; CHEMBL375126; SCHEMBL5426477; BDBM22796; CHEBI:92273; KS-00001DBG; CTK5E6556; cid_1901244; DTXSID30365533; EX-A147; AOB2639; MolPort-002-181-853; HMS3651L12
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1901244
ChEBI ID
CHEBI:92273
CAS Number
CAS 79183-19-0
TTD Drug ID
DMX71K9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [2]
PACTIMIBE DM0NZDT Arteriosclerosis BD40 Phase 2/3 [3]
K-604 DMQVN6P Arteriosclerosis BD40 Phase 2 [4]
Eldacimibe DML7WP0 Hyperlipidaemia 5C80 Phase 2 [5]
GR148672X DM7W6YN Acute lymphoblastic leukaemia 2A85 Clinical trial [6]
Avasimibe DMFG4OM Peripheral vascular disease BD4Z Discontinued in Phase 3 [7]
E-5324 DM562BM Hyperlipidaemia 5C80 Discontinued in Phase 2 [8]
RP-64477 DMTQ3BS Hyperlipidaemia 5C80 Discontinued in Phase 2 [9]
CI-976 DMBO28J Hyperlipidaemia 5C80 Discontinued in Phase 2 [10]
CL-283796 DM7LIDT Hyperlipidaemia 5C80 Discontinued in Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cholinesterase (BCHE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hexafluronium bromide DMFY307 Spasm MB47.3 Approved [12]
MEPTAZINOL DMPSB8F Pain MG30-MG3Z Approved [13]
Eptastigmine DMTV7ZM Cognitive impairment 6D71 Phase 3 [14]
(-)-Phenserine DMNCY1I Alzheimer disease 8A20 Phase 3 [15]
Plasma derived human butyrylcholinesterase DMF3IBC Neurotoxicity NE61 Phase 1 [16]
Protexia DME1Y9W Alzheimer disease 8A20 Phase 1 [17]
JES-9501 DMYR3IE Alzheimer disease 8A20 Phase 1 [18]
Tetra-hydro-isoquinoline derivative 3 DMCZA45 N. A. N. A. Patented [19]
Tetra-hydro-isoquinoline derivative 1 DML86IO N. A. N. A. Patented [19]
Tetra-hydro-isoquinoline derivative 2 DM5CKVF N. A. N. A. Patented [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholinesterase (BCHE) TTEB0GD CHLE_HUMAN Inhibitor [1]
Liver carboxylesterase (CES1) TTMF541 EST1_HUMAN Inhibitor [1]

References

1 Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85.
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33.
4 A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7.
5 Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
7 New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66.
8 Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis. 1994 Jun;107(2):187-201.
9 RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol. 1996 Feb 23;51(4):413-21.
10 Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis. 1995 Jan 6;112(1):7-17.
11 ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J Lipid Res. 1995 Jun;36(6):1199-210.
12 Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
13 Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
14 Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
15 Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
16 Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
17 In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
18 Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
19 A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.